Table 1.
Cancer Type | Model Systems | Study Description | Molecular Effects | Ref. |
---|---|---|---|---|
NLRC5 as a tumor suppressor | ||||
Melanoma | Murine B16.F10 cell line stably expressing NLRC5 | NLRC5 limits tumor growth and metastasis in C57BL/6 mice by activating antitumor CD8+ T lymphocytes; | NLRC5 upregulates MHC-I, β2M, PSMB9, PSMB8, TAP1 gene expression; NLRC5 promotes presentation of peptide from gp100 (Pmel-1) tumor antigen |
[208] |
Melanoma | PRMT5 knockdown in B16.F10 and Yummer1.7 cell lines; B16.F10 stably expressing NLRC5 |
Induction of endogenous NLRC5 by PRMT5 knockdown, or stable NLRC5 expression inhibited tumor growth in C57BL/6 mice | PRMT5 reduces NLRC5 expression by promoting methylation of Arg residues on histones | [176] |
Melanoma | Jak1−/−B16 cell line expressing NLRC5 | NLRC5 rendered Jak1−/− B16 cells susceptible to killing by adoptively transferred Pmel-1 TCR transgenic CD8+ T cells in vivo | NLRC5 upregulates MHC-I | [210] |
Pancreatic adeno-carcinoma (PDAC) | Murine Panc02 cell line expressing a model antigenic peptide SIYRYYGL fused to GFP (Panc02SIY100) | Gamma irradiation induces NLRC5 expression renders Panc02 cells susceptible to anti-PD-L1 in vivo; Stable NLRC5 expression in Panc02SIY100 promotes activation of 2C TCR transgenic CD8+ T lymphocytes |
Gamma irradiation induces MHC-I independently of IFN-I signaling | [178] |
NLRC5 as a tumor promoter | ||||
Hepatocellular carcinoma (HCC) | Human HCC specimens; HCC cell lines: HepG2, SMMC-7721, BEL-7402; stable expression or knockdown of NLRC5 |
HCC specimens and cell lines display elevated NLRC5 expression; NLRC5 promotes cell proliferation, migration and invasion; NLRC5 knockdown has opposite effect & reduces HepG2 tumor growth in nude mice | NLRC5 expression promotes Wnt/β-catenin signaling and c-Myc, CyclinD1, MMP3 expression; β-catenin inhibitor iCRT3 attenuated the effects of NLRC5 overexpression | [211] |
Hepatocellular carcinoma | HepG2 cell line | NLRC5 overexpression in HepG2 cells promotes cell growth via upregulating VEGF-A | NLRC5 promotes VEGF-A expression via AKT activation | [213] |
Clear cell renal cell carcinoma (ccRCC) | Human ccRCC specimens Human ccRCC cell lines Caki-1, 786-O and 769-P |
ccRCC specimens and cell lines display elevated NLRC5 expression; NLRC5 promotes cell proliferation, migration and invasion; NLRC5 knockdown causes opposite effects and reduces 786-O tumor growth in nude mice | NLRC5 promotes β-catenin, c-Myc, CyclinD1, MMP2, MMP9 expression | [212] |
Giloma | Human glioma tissues, cell lines U87, U251 | High grade glioma tissues and cell lines display elevated NLRC5 expression due to high levels of lncRNA SCAMP1; NLRC5 knockdown restrains cell proliferation, migration & invasion and increases apoptosis | SCAM1-1 sponges off miR-499a-5p, which targets LMX1A; LM1A binds NLRC5 promoter and is proposed to augment NLRC5 expression to activate the Wnt/β-catenin pathway | [192] |
Esophageal squamous cell carcinoma (ESCC) | ESCC cell lines | NLRC5 overexpression in ESCC cell lines promotes cell proliferation, colony formation and cell cycle progression | miR-4319 targets NLRC5; low miR-4319 in ESCC upregulates NLRC5 expression | [215] |
Breast cancer | Breast cancer tissues, cell lines MCF-7, MDA-MB-231 |
MCF-7 and MDA-MB-231 show increased proliferation, migration and invasion due to elevated expression of XIST lncRNA, which upregulates NLRC5 | XIST sponges off miR-125b-5p, which targets NLRC5 |
[197] |